These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34143301)

  • 21. Cardiovascular events and death in Japanese patients with chronic kidney disease.
    Tanaka K; Watanabe T; Takeuchi A; Ohashi Y; Nitta K; Akizawa T; Matsuo S; Imai E; Makino H; Hishida A;
    Kidney Int; 2017 Jan; 91(1):227-234. PubMed ID: 27884399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE).
    Yuan Q; Wang J; Peng Z; Zhou Q; Xiao X; Xie Y; Wang W; Huang L; Tang W; Sun D; Zhang L; Wang F; Zhao MH; Tao L; He K; Xu H;
    J Transl Med; 2019 Mar; 17(1):86. PubMed ID: 30876475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
    Kent S; Schlackow I; Lozano-Kühne J; Reith C; Emberson J; Haynes R; Gray A; Cass A; Baigent C; Landray MJ; Herrington W; Mihaylova B;
    BMC Nephrol; 2015 Apr; 16():65. PubMed ID: 25924679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Grams ME; Yang W; Rebholz CM; Wang X; Porter AC; Inker LA; Horwitz E; Sondheimer JH; Hamm LL; He J; Weir MR; Jaar BG; Shafi T; Appel LJ; Hsu CY;
    Am J Kidney Dis; 2017 Sep; 70(3):337-346. PubMed ID: 28366517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
    Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
    Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular disease in patients with chronic kidney disease.
    Jaradat MI; Molitoris BA
    Semin Nephrol; 2002 Nov; 22(6):459-73. PubMed ID: 12430090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dyslipidemia in Patients with Kidney Disease.
    Thobani A; Jacobson TA
    Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric CKD and cardiovascular disease.
    Safder O; Al sharif S; Kari JA
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(3):177-84. PubMed ID: 24720458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal hypertension and cardiovascular disorder in children with chronic kidney disease.
    Peco-Antić A; Paripović D
    Srp Arh Celok Lek; 2014; 142(1-2):113-7. PubMed ID: 24684043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Correa S; Pena-Esparragoza JK; Scovner KM; Waikar SS; Mc Causland FR
    Am J Kidney Dis; 2020 Jul; 76(1):32-41. PubMed ID: 31864821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
    Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
    Lioufas NM; Pedagogos E; Hawley CM; Pascoe EM; Elder GJ; Badve SV; Valks A; Toussaint ND;
    Am J Nephrol; 2020; 51(3):201-215. PubMed ID: 32023606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adolescents and Young Adults with Chronic or End-Stage Kidney Disease.
    Ferris ME; Miles JA; Seamon ML
    Blood Purif; 2016; 41(1-3):205-10. PubMed ID: 26765837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].
    Omata M; Fukagawa M; Kakuta T
    Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health and wealth in children and adolescents with chronic kidney disease (K-CAD study).
    Wong G; Medway M; Didsbury M; Tong A; Turner R; Mackie F; McTaggart S; Walker A; White S; Howard K; Kim S; Craig JC
    BMC Public Health; 2014 Apr; 14():307. PubMed ID: 24708535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients.
    Lee SA; Lee MJ; Ryu GW; Jhee JH; Kim HW; Park S; Jung SY; Oh HJ; Park JT; Han SH; Kang SW; Yoo TH
    Osteoporos Int; 2016 Sep; 27(9):2717-2726. PubMed ID: 27216997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Effectiveness of Medical Therapy, Percutaneous Revascularization, and Surgical Coronary Revascularization in Cardiovascular Risk Subgroups of Patients With CKD: A Retrospective Cohort Study of Medicare Beneficiaries.
    Charytan DM; Natwick T; Solid CA; Li S; Gong T; Herzog CA
    Am J Kidney Dis; 2019 Oct; 74(4):463-473. PubMed ID: 31255335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.